Emerging Role of Garcinol in Targeting Cancer Stem Cells of Non-small Cell Lung Cancer
- 11 Downloads
Garcinol is a polyisoprenylated benzophenone analogue primarily isolated from the dried rind of Garcinia indica, a tropical fruit widely grown in Southeast Asia and Central Africa. Recent findings have well documented that garcinol is a potential dietary phytochemical candidate in the prevention and treatment of cancer and oxidative-related illness. Herein, a brief structure-activity relationship (SAR) is summarized in this review to disclose the connection between the chemical structure of garcinol and its biological activity. Non-small cell lung cancer (NSCLC) is a predominant type of lung cancer, exhibiting an extremely high mortality rate as a result of failing to clean up cancer stem cells (CSCs). Interestingly, garcinol was reported to be able to target and suppress CSCs, and both in vitro and in vivo evidences have revealed the outstanding anti-NSCLC potential of garcinol. The mechanism may involve cellular senescence and apoptosis induction, as well as cell cycle arrest. This paper will review the current progress of garcinol against various tumors in vitro and in vivo, particularly the effects on NSCLC, and summarize the critical structural features of garcinol as a potent anticancer candidate. Also, we will discuss potential future challenges in research and development of garcinol.
KeywordsGarcinol Structure-activity relationship Anticancer Non-small cell lung cancer Cancer stem cells
This study received support from the National Natural Science Foundation of China (grant numbers 31571832 and 81803548), Key Program of Tianjin Municipal Health Bureau (grant number 2013-GG-05), and Tianjin Innovative Research Team Grant (grant number TD-13-5087), and Open Grant from Tianjin Key Laboratory of Food Biotechnology (TJCU-KLFB-18201).
Compliance with Ethical Standards
Conflict of Interest
The authors declare no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
- 3.Hu Y, Fu L. Targeting cancer stem cells: a new therapy to cure cancer patients. Am J Cancer Res. 2012;2(3):340–56.Google Scholar
- 8.Braakhuis AJ, Campion P, Bishop KS. Reducing breast cancer recurrence: the role of dietary polyphenolics. Nutrients. 2016;8(9).Google Scholar
- 15.Li F, Shanmugam MK, Siveen KS, Wang F, Ong TH, Loo SY, et al. Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers. Oncotarget. 2015;6(7):5147–63.Google Scholar
- 26.Balasubramanyam K, Altaf M, Varier RA, Swaminathan V, Ravindran A, Sadhale PP, et al. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J Biol Chem. 2004;279(32):33716–26.CrossRefGoogle Scholar
- 37.Rakoff-Nahoum S. Why cancer and inflammation? Yale J Biol Med. 2006;79(3–4):123–30.Google Scholar
- 41.Ziaei S, Halaby R. Immunosuppressive, anti-inflammatory and anti-cancer properties of triptolide: a mini review. Avicenna J Phytomed. 2016;6(2):149–64.Google Scholar
- 52.Ho YS, Chen CH, Wang YJ, Pestell RG, Albanese C, Chen RJ, et al. Tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induces cell proliferation in normal human bronchial epithelial cells through NFkappaB activation and cyclin D1 up-regulation. Toxicol Appl Pharmacol. 2005;205(2):133–48.CrossRefGoogle Scholar